Abivax in no rush for a deal, confident key June trial data can secure better terms for partnerships, CEO tells CNBC

Late‑Q2 readout of Abivax's second late‑stage maintenance trial for obefazimod is the key upcoming event, with the company targeting a potential FDA filing in Q4 if results are positive. CEO Marc de Garidel said Abivax is likely to raise a combination of equity and debt in late June to reach profitability; the company reported €530m cash at end‑2025 and 2025 R&D expenses rose €31.2m to €177.8m. Shares have been volatile amid takeover speculation (up nearly 1,700% in 2025), but MFN drug‑pricing risks and limited commercial capacity (~150 employees) could constrain deal dynamics and global launch plans.

Analysis

The MFN pricing backdrop materially compresses the expected ex‑US economics for any partner and therefore changes deal structure more than headline chatter implies: buyers will prefer lower upfronts with higher opt‑in royalties or region‑limited rights to preserve U.S. pricing optionality. That reduces near‑term takeover multiple by 10–30% versus a world without MFN, raising the chance bidders push for earnouts tied to real world evidence and payer net prices rather than pure clinical milestones.

Operationally, the company’s pivot to build a commercial footprint while still small creates a bifurcated capital path — modest near‑term financing to maintain operations vs a larger, valuation‑sensitive raise to fund launch readiness. Expect the issuer to favor liability‑light instruments (convertibles, structured equity lines, or priced follow‑ons sized to key hires) that minimize immediate dilution but transfer repricing risk to public markets within weeks of a readout pop.

Market microstructure will amplify moves: implied volatility on this name will spike into the maintenance readout and remains elevated through any subsequent fundraise announcement, creating fertile ground for premium sellers who can stomach binary event risk. The consensus appears to price a near‑perfect readout; the true arb is the interaction between a clinical win, MFN‑constrained ex‑US deal value, and the inevitable capital raise — any one of which can reverse >40% of upside fast.

Key Decisions for Investors

• Directional hedge into event: Buy ABVX Jan 2027 LEAPS (12–18 months) to capture acquisition/approval optionality, funded by selling 1–2 month post‑readout ATM calls to monetize elevated IV. Timeframe: establish position 2–4 weeks pre‑readout and roll the short calls monthly. Risk/Reward: asymmetric — limited carry cost vs >2x payoff if positive readout or deal; downside capped to premium paid for LEAPs minus collected calls.
• Event arbitrage on financing: Prepare to short ABVX on the announcement of a priced equity offering or large convertible (trade idea: buy 2–4 week put spreads around the deal timetable). Timeframe: immediate execution on deal filing/announcement. Risk/Reward: high probability small gain (10–25% pullback) from dilution; max loss limited to spread width.
• Premium selling play: Sell a straddle/strangle 1–3 weeks before maintenance readout only if you can delta-hedge intraday (requires active management) — collect elevated IV; close by 24 hours pre-readout to avoid binary. Timeframe: short term (days–weeks). Risk/Reward: collects premium with historical win rate on event IV crush, but tail risk is large on a surprise positive result or takeover bid.
• Pair trade vs incumbents: Long ABVX equity exposure via options (6–12 months) paired with a hedge short on a large incumbent with overlapping UC/Crohn’s exposure (e.g., ABBV or JNJ) sized 25–40% of notional. Timeframe: 6–12 months to capture re‑rating or selective market share displacement. Risk/Reward: captures idiosyncratic upside if obefazimod repositions treatment landscape while limiting broader biotech beta.